Release and extracellular metabolism of ATP by ecto-nucleotidase eNTPDase 1–3 in hypothalamic and pituitary cells

Mu-Lan He, Arturo E. Gonzalez-Iglesias, Melanija Tomic & Stanko S. Stojilkovic
Section on Cellular Signaling, Endocrinology and Reproduction Research Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA

Received 23 August 2004; accepted in revised form 22 October 2004

Key words: αT3-1 cells, apyrase, ARL67156, GH3 cells, GT1-7 cells, P2X receptors

Abstract

Hypothalamic and pituitary cells express G protein-coupled adenosine and P2Y receptors and cation-conducting P2X receptor-channels, suggesting that extracellular ATP and other nucleotides may function as autocrine and/or paracrine signaling factors in these cells. Consistent with this hypothesis, we show that cultured normal and immortalized pituitary and hypothalamic cells release ATP under resting conditions. RT-PCR analysis also revealed the presence of transcripts for ecto-nucleotidase eNTPDase 1–3 in these cells. These enzymes were functional as documented by degradation of endogenously released and exogenously added ATP. Blocking the activity of eNTPDases by ARL67156 led to an increase in ATP release in perifused pituitary cells and inhibition of degradation of extracellularly added ATP. Furthermore, the addition of apyrase, a soluble ecto-nucleotidase, and the expression of recombinant mouse eNTPDase-2, enhanced degradation of both endogenously released and exogenously added ATP. The released ATP by resting hypothalamic cells was sufficient to activate and desensitize high-affinity recombinant P2X receptors, whereas facilitation of ATP metabolism by the addition of apyrase protected their desensitization. These results indicate that colocalization of ATP release sites and ecto-nucleotidase activity at the plasma membrane of hypothalamic and pituitary cells provides an effective mechanism for the operation of nucleotides as extracellular signaling molecules.

Abbreviations: [Ca\textsuperscript{2+}]-i – intracellular calcium concentration; eNTPDase – ecto-nucleoside triphosphate diphosphohydrolase; P1Rs – adenosine G protein-coupled receptors; P2XRs – purinergic receptor channels; P2YRs – G protein-coupled purinergic receptors; PRL – prolactin

Introduction

ATP and UTP have to be released by cells to act as extracellular messengers and are then hydrolyzed by ecto-nucleotidases, resulting in the formation of the respective nucleoside and free phosphate. The products of this hydrolytic cascade, ADP, UDP and adenosine, also act as extracellular messengers by activating distinct plasma membrane receptors in numerous excitable and non-excitable cells [1]. These receptors were termed purinergic and they belong to two groups: P1 receptors (P1Rs) that are activated by adenosine and P2 receptors (P2Rs) that recognize mainly ADP, ATP, UDP and UTP. Two families compose P2Rs: The ligand-gated channel family (P2XR) and the G protein-coupled receptor family (P2YR) [2]. Initially, it was believed that single enzymes exist for the hydrolysis of ATP (ecto-ATPase), ADP (ectoADPase) and AMP (ecto-5'-nucleotidase), and that these enzymes are expressed on the plasma membrane with their catalytic domain facing the extracellular space [3]. Currently identified ecto-nucleotidases include members of the ecto-nucleoside triphosphate diphosphohydrolase family of enzymes (eNTPDase) and several other subfamilies of enzymes. Three out of six known eNTPDases (termed eNTPDase-1, -2, and -3) are expressed in plasma membrane and, like P2XRs, are composed of two transmembrane domains, which place most of the protein extracellularly and its N- and C-termini intracellularly. These enzymes not only hydrolyze extracellular ATP and/or ADP to AMP, but also metabolize other nucleotide tri- and diphosphates, including UTP and UDP [1].

Normal and immortalized anterior pituitary cells express A\textsubscript{1}, A\textsubscript{2A} and A\textsubscript{2B} subtypes of P1 receptors [4–6]. Several earlier published reports have also indicated the expression of P2Rs in anterior pituitary [7–14]. The first P2 receptor identified in this tissue was P2Y\textsubscript{1R} [15]. Recently, we showed the presence of transcripts for four additional
members of P2YRs: P2Y_1, P2Y_4, P2Y_6 and P2Y_12 in anterior pituitary cells and identified the P2Y_1R subtype in lactotroph fraction of cells [16]. Earlier studies revealed the expression of P2X_2R and its spliced form P2X_2bR in somatotrophs and gonadotrophs [17, 18], as well as P2X_3R, P2X_4R and P2X_5R in other pituitary cell types [17, 19]. In lactotrophs, the P2X_3R subtype provides a major pathway for calcium-influx-dependent signaling and prolactin (PRL) secretion [16]. Thus, of the 17 known nucleotide receptors, 12 are probably expressed in the secretory anterior pituitary. The non-secretory anterior pituitary cells as well as both neuronal and intermediate lobes of pituitary also express functional P1/P2 receptors [9, 20–23]. In that respect, only the brain expresses more of these receptor subtypes, indicating the potential relevance of nucleotide-dependent receptor signaling pathways in pituitary cell functions.

In contrast to the well-documented expression of P1Rs and P2Rs in pituitary cells, the knowledge about the release of purines and pyrimidines by pituitary cells is limited to two reports. Chen et al. [24] reported that calcium ionophore A23187 induced release of ATP from pituitary cells in a concentration- and calcium-dependent manner. Tomic et al. [14] observed a GnRH-induced increase in ATP release in perfused pituitary cells. To our knowledge, the expression and role of ecto-nucleotidases in controlling the extracellular messenger functions of nucleotides has not been previously established in pituitary cells. Here we studied the release of ATP in normal and immortalized pituitary cells as well as in GnRH-secreting GT1-7 neurons. In addition, we addressed the efficacy of the released ATP to activate receptors. We also characterized the capacity of these cells to metabolize the endogenously released and exogenously added ATP. The expression of transcripts for eNTPDase 1–3 was also analyzed, as well as the inhibition of ATP degradation by ARL67156, a blocker of these enzymes.

Materials and methods

Cell cultures and treatments

Experiments were performed in anterior pituitary cells from normal postpubertal female Sprague–Dawley rats obtained from Taconic Farm (Germantown, NY), immortalized mouse αT3-1 gonadotrophs, mouse AtT20 corticotrophs, rat GH_3 lacto-somatotrophs, as well as in mouse GnRH-secreting hypothalamic GT1-7 cells. Pituitary cells were dispersed as described previously [25] and cultured as mixed cells in medium 199 containing Earle’s salts (Invitrogen, Carlsbad, CA), sodium bicarbonate, 10% heat-inactivated horse serum, 2.5% fetal bovine serum, and 100 μg/ml gentamicin. GH_3 immortalized pituitary cells (ATCC, Manassas, VA) were cultured in F12K Nutrient Mixture with Kaingh’s modification supplemented with 1.5 g/l sodium bicarbonate, 15% heat-inactivated horse serum, 2.5% fetal bovine serum, and 100 μg/ml gentamicin. Cells were treated with ATP (Sigma, St. Louis, MO), apyrase (grade I, Sigma) and ARL67156 (Tocris, Ellisville, MO).

Measurements of ATP and PRL

ATP content was monitored using cells in static cultures and column perfusion experiments. For static culture experiments, cells were seeded at different densities in poly-d-lysine-coated wells and cultured at 37 °C for 24 h. Before assay, cells in each well were washed twice with 1 ml of ATP-free Krebs–Ringer buffer (120 mM NaCl, 5 mM KCl, 1.26 mM CaCl_2, 0.7 mM MgSO_4, 10 mM Glucose, and 15 mM HEPES, pH 7.4). Then, cells were incubated in 1 ml per well of fresh ATP-free or ATP containing buffer. At the indicated times, samples (~0.6 ml of supernatant) were collected and ATP concentration measured immediately. For perfusion experiments, 5 × 10^6 cells were incubated with preswollen cytodex-1 beads in 60-mm Petri dishes for 24 h. The beads with and without cells were then transferred to 0.5-ml chambers and perfused with Krebs–Ringer medium containing 0.1% BSA for 2.5 h at a flow rate of 0.8 ml/min and at 37 °C. Fractions were collected in 1-min intervals and immediately assayed for ATP contents using an ATP bioluminescent assay kit (Sigma) in TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA). Calibration curves were constructed from measurements of standard solutions, which were diluted in the same medium as the corresponding solutions of unknown ATP concentration. Detection limit of the assay was 0.2 nM. PRL content in culture samples was determined by radioimmunoassay. Primary antibody and standard for PRL assay were provided by the National Pituitary Agency and Dr AF Parlow (Harbor-UCLA Medical Center, Torrance, CA). I^25-I-PRL was purchased from Perkin-Elmer Life Sciences (Boston, MA) and secondary antibody from Sigma.

Reverse transcriptase-PCR analysis of eNTPDase expression

Total RNA from rat anterior pituitary and hypothalamic tissues and cultured cells was extracted using TRIzol reagent (Invitrogen). After DNase I digestion, 2 μg of total RNA was reverse-transcribed into first-strand cDNA with oligo-dT primers and SuperScriptII reverse transcriptase (Invitrogen). The cDNAs were then amplified with different eNTPDase isoform-specific primer sets in the non-conserved region. The oligonucleotide sequences of primers used for PCR amplification, with GenBank accession numbers given in parentheses, are listed as: mouse

1. ARL67156, a blocker of these enzymes.
eNTPDase-1 (AF037366): sense (1,389–1,409 bp, 5'-CAA-GATCAAAGACAGCAACGC-3'), antisense (1,583–1,604 bp, 5'-TCTTGTCATACGACTCTCCTTTCC-3'); mouse eNTPDase-2 (AF042811): sense (1,217–1,235 bp, 5'-CTGG-CACTGTAAGCCATGGTC-3'), antisense (1,533–1,554 bp, 5'-GAAGAGAGATAGCGGGAGTTG-3'); mouse eNTPDase-3 (NM-178676): sense (1,485–1,504 bp, 5'-GATTCCATCTACCACCATACGC-3'), antisense (1,684–1,704 bp, 5'-TGGTGTGGTGACTCTGGTG-3').

The amplification was conducted in a Robocycler Thermal Cycler (Stratagene, La Jolla, CA) in a 50-μl reaction volume containing 1 μl of the first-strand cDNA as template, 1 unit of Taq DNA polymerase (Invitrogen), 0.5 μM concentration of each primer, 0.2 mM dNTP, and 1 μl PCR buffer (2 mM MgCl₂, 50 mM KCl, 20 mM Tris-HCl, pH 8.4). Amplification of DNA templates was initiated by a denaturation step at 94°C for 180 s, followed by 35 cycles of denaturing at 94°C for 45 s, annealing at 52°C for 60 s, and extension at 72°C for 60 s. The reaction was then terminated by a final extension step at 72°C for 10 min. After PCR, a 10-μl aliquot of PCR products was size-fractionated by electrophoresis in a 1.2% agarose gel and terminated by a final extension step at 72°C for 10 min.

The coding sequences of the rat P2X₂ and P2X₃ subunits were isolated by RT-PCR [26], and subcloned into bisscistrionic enhanced green fluorescent protein expression vector, pIRE2-EGFP (Clontech, Palo Alto, CA) at the restriction enzyme site of pXol/PSL for P2X₂R and XhoI/EcoRI for P2X₃. Chimeric P2X₂₃/P2X₃ subunit contain extracellular domain from VaL₁₆₀ to Phe₃₀¹ of P2X₂R instead of the native Ile₆₆-Tyr₃₁₀ sequence of P2X₂R and was constructed as reported previously [27]. Mouse eNTPDase-2 cDNA clone (MGC clone 5806) was purchased from Invitrogen and the full-length cDNA fragment was released by Xhol/EcoRI digestion and then directionally subcloned into mammalian expression vector, pcDNA3.1/V5HisA (Invitrogen). Plasmid DNAs for transfection were prepared using a QIAGEN Plasmid Maxi Kit (Qiagen, Germany). Before the day of transfection, mouse GT1-7 cells or αT3-1 cells were plated on 35 mm culture dishes or poly-L-lysine coated 6-well plates. For each dish of cells, transient transfection of expression constructs was performed using 1 μg DNA and 7 μl LipofectAMINE 2000 reagent (Invitrogen) in 3 ml serum-free OPTI-MEM. After 6 h of incubation, transfection mixture was replaced with normal culture medium. Cells were subjected to experiments 24–48 h after transfection.

### Calcium measurements

Transfected GT1 cells (100,000 per 35 mm coverslip) were preloaded with 1 μM Fura-2 acetoxyethyl ester (Fura-2/AM; Molecular Probe, Eugene, OR) for 60 min at room temperature in Krebs Ringer medium. After dye loading, cells were incubated in Krebs Ringer medium and kept in the dark for at least 30 min before single-cell intracellular calcium concentration ([Ca²⁺]) measurements. Covalsips with cells were mounted on the stage of an Axiovert 135 microscope (Carl Zeiss, Oberkochen, Germany) attached to the Attofluor Digital Fluorescence Microscopy System (Atto Instruments, Rockville, MD). Cells were stimulated with ATP and the dynamic changes of [Ca²⁺], were examined under a 40 × oil immersion objective during exposure to alternating 340- and 380-nm light beams, and the intensity of light emission at 520 nm was measured. The ratio of light intensities, F₃₄₀/F₃₈₀, which reflects changes in [Ca²⁺], was simultaneously followed in several single cells. EGFP was used as a marker for selection of cells expressing P2XR. Cells expressing EGFP were optically detected by an emission signal at 520 nm when excited by 488-nm ultraviolet light. Experiments were done in cells with comparable GFP fluorescence intensities (about 60 arbitrary units) and no repetitive stimulation was done to avoid the possible impact of desensitization on the amplitude and pattern of [Ca²⁺], signals.

### Results

The release of ATP was studied in hypothalamic and pituitary cells in static culture and in perfusion. In static cultures of GT1-7, αT3-1 and GH₃ cells, the replacement of medium was used as stimulus for ATP release. In general, the release of ATP was dependent on cell number and duration of incubation. As shown in Figure 1a, within 5 min after the addition of ATP-free fresh medium to 1 × 10⁵ GT1-7 cells there was an accumulation of ATP to about 80 nM ATP, whereas in medium from dishes with 5 × 10⁵ cells the measured ATP concentration was about 160 nM. In medium from dishes without cells there was practically no measurable ATP. Further incubation of cells was followed by a progressive decrease in ATP concentrations in medium. The release of ATP was not unique for GT1-7 cells, but was also observed in pituitary cells. Figure 1b compares the time course of ATP release in GT1-7, GH₃ and αT3-1 cells; in all cultures a rapid ATP release during the first 5 min of incubation was followed by a progressive decrease in ATP concentrations as their incubation times were extended (Figure 1b).
In general, a rapid ATP release after the change of medium could reflect lysis of cells. However, two lines of evidence argue against this hypothesis. First, the cell viability and integrity was routinely evaluated by the addition of trypan blue and no changes were detected during 60-min incubation. Second, a rapid lysis of cells should also be reflected on hormone release, but that was not the case in experiments with GH3 cells. As shown in Figure 1c, in these cells there was a small PRL release during the first 5 min of incubation, followed by a progressive increase in PRL release at extended incubation times. The dissociation between the time-course of ATP and hormone accumulation in the medium from GH3 cells indicates that ATP release occurs through either a pathway other than the exocytotic, or that ATP, but not PRL, is degraded and therefore a progressive decrease in extracellular ATP concentrations in static cultures after replacement of medium reflects the time needed to reach a balance between ATP release and its degradation by ectonucleotidases.

In additional experiments aimed to further exclude the possible impact of lysis of cells on ATP release, GT1-7, αT3-1 and GH3 cells were attached on beads and perfused for 150 min with ATP-free buffer at flow rate of 0.8 ml/min, prior to sample collection for ATP measurements. This time was sufficient to stabilize basal hormone secretion, as illustrated in Figure 2a for PRL release by perfused GH3 cells. In the same samples there were measurable levels of ATP, indicating that perfused GH3 cells also release this nucleotide (Figure 2b). Consistent with the findings in cells in static cultures, ATP was also released by perfused GT1-7 and αT3 cells (Figure 2b). Again, there was no strict correlation between ATP and PRL secretory profiles in perfused GH3 cells.

Expression and activity of ecto-nucleotidase (eNTPDase) 1–3

To clarify whether the plasma membrane-associated ecto-nucleotidases are expressed in these cells, RT-PCR analysis

In general, a rapid ATP release after the change of medium could reflect lysis of cells. However, two lines of evidence argue against this hypothesis. First, the cell viability and integrity was routinely evaluated by the addition of trypan blue and no changes were detected during 60-min incubation. Second, a rapid lysis of cells should also be reflected on hormone release, but that was not the case in experiments with GH3 cells. As shown in Figure 1c, in these cells there was a small PRL release during the first 5 min of incubation, followed by a progressive increase in PRL release at extended incubation times. The dissociation between the time-course of ATP and hormone accumulation in the medium from GH3 cells indicates that ATP release occurs through either a pathway other than the exocytotic, or that ATP, but not PRL, is degraded and therefore a progressive decrease in extracellular ATP concentrations in static cultures after replacement of medium reflects the time needed to reach a balance between ATP release and its degradation by ectonucleotidases.

In additional experiments aimed to further exclude the possible impact of lysis of cells on ATP release, GT1-7, αT3-1 and GH3 cells were attached on beads and perfused for 150 min with ATP-free buffer at flow rate of 0.8 ml/min, prior to sample collection for ATP measurements. This time was sufficient to stabilize basal hormone secretion, as illustrated in Figure 2a for PRL release by perfused GH3 cells. In the same samples there were measurable levels of ATP, indicating that perfused GH3 cells also release this nucleotide (Figure 2b). Consistent with the findings in cells in static cultures, ATP was also released by perfused GT1-7 and αT3 cells (Figure 2b). Again, there was no strict correlation between ATP and PRL secretory profiles in perfused GH3 cells.
was performed using specific primers for three known plasma membrane-associated eNTPDase subtypes. The mRNA transcripts of eNTPDase were expressed in mouse and rat hypothalamic and pituitary cells, as well as in mouse AtT20 pituitary cells and GT1 hypothalamic cells (Figure 3a). All three transcripts were also expressed in rat hypothalamic and pituitary tissues, dispersed pituitary cells cultured for 24 h, and GH3 cells (Figure 3b). However, we were unable to observe the presence of specific transcripts for eNTPDase-1 in mouse /C11 T3-1 immortalized gonadotrophs, whereas the transcripts for the other two isoforms were present in this cell type (Figure 3a).

In order to estimate the capacity of endogenous ecto-nucleotidase to degrade ATP, hypothalamic and pituitary cells were transiently perfused with 10 $\mu$M ATP at flow rate of 0.8 ml/min and the nucleotide concentration was measured in medium prior, during and after ATP application. In media from columns without cells, the measured levels of ATP were between 8.5 and 10 $\mu$M, whereas there was a substantial decrease of ATP concentrations in media from columns containing cells. Figure 4 illustrates that in all cases steady levels of ATP were reached within 2–3 min of nucleotide addition. The level of ATP degradation was dependent on cell type in order: Pituitary cells > GH3 > GT1-7 > αT3-1. These results indicate that eNTPDases expressed in hypothalamic and pituitary cells are functional enzymes and provide an effective mechanism for the control of the extracellular messenger functions of endogenously released ATP.

### Blockade of ecto-nucleotidase activity

We initially used αβ-meATP, a slow degradable agonist [3], to inhibit the endogenous ecto-nucleotidase activity in hypothalamic and pituitary cells. Unfortunately, this compound interfered with ATP measurements in our assay. Therefore, we used ARL67156, a relatively specific blocker of these enzymes [28]. Pituitary cells were perfused with the blocker in order to characterize changes in the levels of both endogenously released and exogenously added ATP. Inhibition of pituitary ecto-nucleotidases by 50 $\mu$M ARL67156 was sufficient to detect an increase in endogenous ATP release. Figure 5a illustrates a progressive increase in ATP concentrations in medium during ARL67156
application to cells perifused at flow rate of 0.8 ml/min, as well as a decrease in medium ATP content after removal of this blocker. These results confirmed not only that the endogenously released ATP was not due to cell lysis, but also that measured ATP concentrations reflect the balance between de novo released and metabolized nucleotide.

Degradation of extracellularly added ATP by perifused pituitary cells was also inhibited in a concentration-dependent manner by ARL67156. However, the majority of ATP was still degraded in the presence of 50 μM ARL67156 (Figure 5b). The effect of this compound on degradation of exogenously added ATP was not only observed in normal pituitary cells but also in perifused GH3 cells. In experimental conditions shown in Figure 5c, about 90% of added ATP (1 μM) was degraded in control GH3 cells and about 70% in 50 μM ARL67156-treated cells. Thus, a rapid and dramatic decrease in exogenously added ATP concentration in perifused cells also reflects a high activity of endogenous ecto-nucleotidase.

**Facilitation of ATP degradation**

To enhance degradation of ATP, two experimental approaches were used: Overexpression of mouse eNTPDase-2 and the addition of apyrase, a plant soluble ecto-nucleotidase. eNTPDase-2 was overexpressed in two cell
Release and metabolism of ATP in pituitary
designed to serve as an example of a document.

lines derived from mouse, αT3-1 and GT1-7 cells. Twenty-four hours after transfection, cells were washed and samples for ATP measurements were collected 5 min after replacing the medium. As shown in Figure 6a, left panel, ATP was released in both vector controls and eNTPDase-2-expressing αT3-1 cells, but the level of ATP measured in cells overexpressing the enzyme was significantly lower. In GT1-7 cells over-expressing mouse eNTPDase type-2, 5-min incubation was sufficient to metabolize the majority of de novo ATP release (Figure 6a, central panel). The exogenously added ATP (200 nM) was also rapidly degraded (Figure 6a, right panel). The addition of apyrase practically masked the endogenously released ATP from both αT3-1 and GT1-7 cells (Figure 6b) and degraded the majority of extracellularly added ATP within 5 min of incubation (Figure 6b, right panel).

Desensitization of P2XRs by endogenously released ATP

To examine the biological activity of endogenously released ATP, we expressed recombinant P2XRs in GT1-7 cells, which do not bear endogenous purinergic receptors [19]. We purposely selected P2X2aR, P2X2bR, P2X3R and two chimeras having the ectodomain of P2X2R in the backbone of P2X2Rs (P2X2a/V60-F301X3 and P2X2b/V60-F301X3), because these receptors differ in their EC50 for ATP: About 50 nM for P2X3R and P2X2aR/V60-F301X3 chima, which is in the range of ATP concentrations in medium from cells in resting conditions (Figure 1) and about 3 μM for P2X2aR and P2X2bR [29]. After replacement of media, cells were either incubated for 15 and 60 min in the absence of apyrase, or incubated for 1–4 h in the presence of apyrase. After the indicated incubation periods, control and apyrase-treated cells were stimulated with 10 μM ATP. Cells treated with apyrase were also stimulated with conditioned media collected from cultures of GT1-7 neurons incubated for 5 min. Single cell calcium measurements were used to detect the activity of receptors upon ATP stimulation.

After 60 min of incubation in medium without apyrase, none of the P2X3R-expressing cells (57 out of 57) showed elevation in [Ca2+]i in response to ATP stimulation (Figure 7a, left panel). Practically, 15 min of incubation in medium without apyrase was sufficient to abolish responsiveness of the majority of P2X3R-expressing cells and only in a small fraction of cells a small amplitude [Ca2+]i signal was observed (Figure 7a, central panel). In cultures incubated for 60 min with apyrase-containing medium, the responsiveness to ATP was established in all (49 out of 49) cells, clearly indicating that the endogenously released ATP was sufficient to activate and desensitize these receptors (Figure 7a, right panel). Consistent with this conclusion, in apyrase-treated GT1-7 neurons expressing P2X3R the addition of conditioned medium from resting cells triggered response in some (23 out of 41) cells (data not shown).

Under resting conditions, 60-min incubation also led to the loss of responsiveness of all P2X2aR/V60-F301X3 and P2X2bR/V60-F301X3-expressing cells (85 out of 85, combined together for both receptors; Figures 7b and c, left panels). In a substantial fraction of cells incubated for 15 min (24 out of 73 cells) basal [Ca2+]i was elevated and the addition of ATP led to further increase in [Ca2+]i, followed by a progressive decrease below the initial values (Figures 7b and c, central panels). In cells bathed in apyrase (1 microgram/ml)-containing medium for 4 h, ATP induced typical a pattern of calcium signals, determined by the rates of activation and desensitization of receptors (Figures 7b and c, right panels). In apyrase-pretreated cells, the addition of conditioned medium collected from resting cells elevated [Ca2+]i, in 21 out of 46 cells, confirming that...
the released ATP from resting cells is sufficient to reach the threshold level for activation of these receptors (data not shown).

In contrast to P2X$_1$R and chimeric receptors, all P2X$_2$R and P2X$_3$R-expressing cells responded to ATP stimulation independently of the duration of resting period and presence/absence of apyrase (Figures 7d and e), indicating that in these experimental conditions the level of endogenously released ATP is below the threshold dose required for activation and desensitization of these two receptors. In accordance with this, conditioned media from resting cells triggered [Ca$^{2+}$]$_i$ signals in none of the P2X$_2$R and P2X$_3$R-expressing cells (35 out of 35; data not shown). All together, these results indicate that endogenously released ATP is biologically active and that in vitro released ATP levels are sufficient to activate and desensitize high affinity receptors.

Discussion

The presence of phospholipase C-coupled P2YRs was initially observed in a mixed population of sheep pituitary cells [12, 13]. Subsequent studies showed that rat pituitary cells also express P2YRs; their activation by ATP is associated with an elevation in [Ca$^{2+}$]$_i$, due to release of calcium from intracellular stores [10, 11, 30]. Molecular cloning and functional characterization of rat P2YRs in the pituitary revealed the expression of P2Y$_2$R with the pharmacological profile resembling the one observed in sheep pituitary cells [15]. Additional studies have suggested the presence of P2XRs in normal and immortalized pituitary cells [8, 9, 14]. Initially, the mRNAs for P2X$_2$R and its spliced form, P2X$_2$bR, were found in pituitary cells and functional receptors were identified in gonadotrophs and somatotrophs [18, 19, 31, 32]. This was followed by discovery of transcripts for P2X$_1$R, P2X$_2$R, and P2X$_7$R in pituitary cells [17], and the finding that lactotrophs express P2X$_7$R, which plays a major role in control of calcium-influx-dependent PRL release [16]. Transcripts for P2X$_1$R, P2Y$_1$R, and P2Y$_2$R have also been detected in anterior pituitary cells and functional P2Y$_2$R were identified in lactotrophs [16]. Adenosine also operates as an extracellular messenger in anterior pituitary cells by activating A$_1$, A$_2A$, and A$_2B$ receptors [5]. Such a complex expression pattern of P1Rs and P2Rs is consistent with the hypothesis that purinergic receptors play important roles in control of anterior pituitary functions.

The physiological sources of extracellular nucleotides required for activation of these receptors in pituitary cells remains largely uncharacterized. Here we show that ATP is released by normal and immortalized pituitary cells, as well as by GT1-7 cells, at resting conditions. Three lines of evidence argues against the hypothesis that lysis of cells underlies ATP release. A rapid increase in ATP release in GH$_3$ cells in static cultures after medium replacement was not accompanied with rapid PRL release. ATP was also released by pituitary cells perfused for 2.5 h at flow rate of 0.8 ml/min. Finally, there is a gradual and transient increase in the rate of ATP release in the presence of ARL67156. In general, neurons, neuroendocrine cells and platelets release ATP by calcium-controlled exocytosis of nucleotides stored within synaptic vesicles or dense core granules [33]. Since anterior pituitary cells secrete hormones by exocytotic pathway, it is reasonable to postulate that ATP is also released through the same pathway. However, in this study we were unable to observe a correlation between ATP and PRL release in resting GH$_3$ cells. It is well established that purinergic receptors are also expressed in cell types that do not secrete by exocytosis [2]. This suggests that ATP could also be released by another mechanism, but the nature of this pathway is not known at the present time [34]. Both secretory and non-secretory ATP release pathways are probably operative in human astrocytes [35], whereas further studies are needed to clarify which mechanism is responsible for ATP release in pituitary cells.

Although the action of ATP as an autocrine/paracrine factor is critically dependent on its rapid metabolism by ecto-nucleotidases, the expression and role of these enzymes in control of nucleotide-dependent signaling in pituitary cells was not previously addressed. Here we provide evidence that these enzymes are expressed and operative in hypothalamic and pituitary cells. First, we show that transcripts for three plasma membrane-located eNTPDases are expressed in hypothalamic and pituitary tissues, cultured pituitary cells and immortalized lacto-somatotrophs, corticotrophs, gonadotrophs and GnRH-secreting cells. We also show that these enzymes are capable of degrading both endogenously released and exogenously added ATP. Depending on the cell type, 5 × 10$^5$ cells perfused at flow rate of 0.8 ml/min were able to degrade 27%–70% of extracellularly added ATP. Finally, we show the impact of inhibition of these enzymes on ATP degradation. Thus, the ATP concentration measured in our experimental conditions reflects the equilibrium between the rate of ATP release and the rate of ATP hydrolysis by endogenously expressed ecto-nucleotidases.

In general, there are three possible ways to attenuate the endogenous ecto-nucleotidase activity in a particular cell type: Removal of calcium, addition of slow-metabolizing agonists and application of ecto-nucleotidase-specific inhibitors. The activity of these enzymes depends on extracellular calcium concentration [3]. However, calcium is also required for activation of exocytosis, which in lactotrophs and somatotrophs occurs in the absence of agonist stimulation and is driven by spontaneous voltage-gated calcium influx [36]. Thus, removal of calcium also affects both hormone secretion and the associated ATP co-secretion. The ecto-nucleotidases are also blockable by αβ-methylene ATP [3], but this slow metabolizing agonist interferes with ATP measurements in our assay, which is not the case for ARL67156, a specific inhibitor for some ecto-nucleotidases. This compound significantly and reversibly inhibited ATP degradation in normal and immortalized pituitary cells. Inhibition of metabolism of ATP by ARL67156 clearly indicates that the released ATP is not due to cell lysis or loss of plasma membrane integrity, but reflects an active process. However, the potency of
ARL67156 to inhibit pituitary ecto-nucleotidase is not high enough, which limits the utility of this blocker for further investigations on the rate and mechanism of ATP release by pituitary cells.

One may speculate that the endogenously released ATP by hypothalamic and pituitary cells is not biologically active or it is below the threshold required for activation of P2Rs. To test this hypothesis, we expressed P2X2R and P2X3R in GT1-7 cells. At the density of \(1 \times 10^5\) cells per 35 mm coverslip, our results indicate that the endogenously released ATP is sufficient to desensitize P2X2/R and P2X2/X3 chimeras, but not P2X3R. This was further supported by the finding that the ATP concentrations in conditioned culture medium are comparable to the EC\(_{50}\) values required for activation of P2X3R. Thus, the endogenously released ATP is biologically active and is able to stimulate at least a fraction of P2R subtypes expressed in these cells. Certainly, these in vitro conditions should not fairly reflect the in vivo situation, where tissue ATP concentration reflects a balance between rates of release, hydrolysis and dilution into intercellular compartment.

Limited information exists about the roles of P2XR in hypothalamic and pituitary cells and the integration of P1Rs in signaling through ecto-nucleotidase-dependent conversion of ATP to adenosine. Stimulation of LH and PRL release by addition of ATP has been previously shown [7, 14, 16]. We may also speculate that the actions of ATP as an autocrine and paracrine factor in pituitary cells, which express numerous P2YRs and P2XRs, provide a potential mechanism for a progressive amplification of ATP secretory response and a dose-dependent activation of specific receptors. Although gap junction channels contribute to synchronized calcium signaling among pituitary cells [37], it is also reasonable to speculate that extracellular ATP plays a role in intercellular propagation of calcium waves between secretory and non-secretory anterior pituitary cell types. Finally, the finding that GT1-7 neurons release ATP but do not express P2Rs may indicate that in vivo GnRH neurons influence other P2R-expressing neurons through ATP-mediated synaptic transmission rather than by GnRH.

In summary, we show that ATP is released by hypothalamic and pituitary cells and is metabolized by ecto-nucleotidases. The release of ATP is not due to lysis of cells but reflects an active process. Moreover, endogenously released ATP is biologically active and its in vitro levels are sufficient to stimulate and desensitize P2X2Rs, according to their ligand affinity. The signaling functions of ATP are inhibited by ARL67156-sensitive ecto-nucleotidases. These results are consistent with the hypothesis that in pituitary cells P2Rs and ecto-nucleotidases compete for a limited pool of endogenously released ATP. The ecto-nucleotide cascade not only terminates the extracellular messenger functions of ATP but also provides a pathway for the generation of ADP and adenosine, which in pituitary cells may activate some P2YRs and P1Rs, respectively. Finally, these enzymes may build up a mechanism for the control of ligand-dependent desensitization of purinergic receptors within the pituitary, which may be relevant to the homeostasis of the gland.

**References**

1. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn-Schmiedeberg’s Arch Pharmacol 2000; 362: 299–309.
2. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413–92.
3. Pearson JD. Ectonucleotidases: Measurement of activities and use of inhibitors. Methods Pharmacol 1985; 6: 83–107.
4. Rees DA, Scanlon MF, Ham J. Novel insights into how purines regulate pituitary cell function. Clin Sci 2003; 104: 467–81.
5. Rees DA, Scanlon MF, Ham J. Adenosine signalling pathway in the pituitary gland: One ligand, multiple receptors. J Endocrinol 2003; 177: 357–64.
6. Kumari M, Buckingham JC, Poyser RH, Cover PO. Roles for adenosine A1- and A2-receptors in the control of thyrotrphin and prolactin release from the anterior pituitary gland. Regul Pept 1999; 79: 41–6.
7. Nunez L, Villalobos C, Frawley LS. Extracellular ATP as an autocrine/paracrine regulator of prolactin release. Am J Physiol 1997; 272: E1117–23.
8. Villalobos C, Alonso-Torre SR, Nunez L, Garcia-Sancho J. Functional ATP receptors in rat anterior pituitary cells. Am J Physiol 1997; 273: C1963–71.
9. Chung HS, Park KS, Cha SK et al. ATP-induced [Ca\(_{2+}\)] changes and depolarization in GH3 cells. Br J Pharmacol 2000; 130: 1843–52.
10. Chen Z-P, Levy A, Mc Ardle CA, Lightman SL. Pituitary ATP receptors: Characterization and functional localization to gonado-tropes. Endocrinology 1994; 135: 1280–4.
11. Chen Z-P, Krutzmeier M, Poeh A et al. Effects of extracellular nucleotides in the pituitary: Adenosine triphosphate receptor-mediated intracellular responses in gonadotrope-derived αT3-1 cells. Endocrinology 1996; 137: 248–56.
12. Van Der Merwe PA, Wakefield IK, Fine J et al. Extracellular adenosine triphosphate activates phospholipase C and mobilizes intracellular calcium in primary cultures of sheep anterior pituitary cells. FEBS Lett 1989; 243: 333–6.
13. Davidson JS, Wakefield IK, Sohmius U et al. A novel extracellular nucleotide receptor coupled to phosphoinositide-C in pituitary cells. Endocrinology 1999; 126: 80–7.
14. Tomic M, Jobin RM, Vergara LA, Stojilkovic SS. Expression of purinergic receptor channels in their role in calcium signaling and hormone release in pituitary gonadotropes. J Biol Chem 1996; 271: 21200–8.
15. Chen Z-P, Krull N, Xu L et al. Molecular cloning and functional characterization of a rat pituitary G protein-coupled adenosine triphosphate (ATP) receptor. Endocrinology 1996; 137: 1833–40.
16. He M-L, Gonzalez-Iglesias AE, Stojilkovic SS. Role of nucleotide P2 receptors in calcium signaling and prolactin release in pituitary lactotrophs. J Biol Chem 2003; 278: 46270–7.
17. Koshimizu T, Tomic M, Wong AOL et al. Characterization of purinergic receptors and receptor-channels expressed in anterior pituitary cells. Endocrinology 2000; 141: 4091–9.
18. Lynch KJ, Touma E, Niforatos W et al. Molecular and functional characterization of human P2X3 receptors. Mol Pharmacol 1999; 56: 1171–81.
19. Koshimizu T, Tomic M, Van Goor F, Stojilkovic SS. Functional role of alternative splicing in pituitary P2X2 receptor-channel activation and desensitization. Mol Endocrinol 1998; 12: 901–13.
20. Troedec JD, Thirion S, Petturiti D et al. ATP acting on P2Y receptors triggers calcium mobilization in primary cultures of rat neurohypophy-seal astrocytes. Pflugers Arch 1999; 437: 745–53.
21. Kapoor JR, Sladek CD. Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release. J Neurosci 2000; 20: 8868–75.
22. Uchiyama M, Nakajima Y, Sakuma Y, Kato M. Purinergic regulation
of intracellular Ca\(^{2+}\) concentration of rat pituitary folliculo-stellate cells in primary culture. J Neuroendocrinol 2001; 13: 378–85.
23. Loesch A, Miah S, Burnstock G. Ultrastructural localization of ATP-gated P2X2 receptor immunoreactivity in the rat hypothalamo-neurohypophyseal system. J Neurocytol 1999; 28: 495–504.
24. Chen Z-P, Kratzmeier M, Levy A et al. Evidence for a role of pituitary ATP receptors in the regulation of pituitary function. Proc Natl Acad Sci USA 1995; 92: 5219–23.
25. Koshimizu T, Van Goor F, Tomic M et al. Characterization of calcium signaling by purinergic receptor-channels expressed in excitable cells. Mol Pharmacol 2000; 58: 936–45.
26. Koshimizu T, Koshimizu M, Stojilkovic SS. Contributions of the C-terminal domain to the control of P2X receptor desensitization. J Biol Chem 1999; 274: 37651–7.
27. Koshimizu T, Ueno S, Tanoue A et al. Heteromultimerization modulates P2X receptor functions through participating extracellular and C-terminal subdomains. J Biol Chem 2002; 277: 46891–9.
28. Sesti C, Koyama M, Broekman MJ et al. Ectonucleotidase in sympathetic nerve endings modulates ATP and norepinephrine exocytosis in myocardial ischemia. J Pharmacol Exp Ther 2003; 306: 238–44.
29. He M-L, Koshimizu T, Tomic M, Stojilkovic SS. Purinergic P2X2 receptor desensitization depends on coupling between ectodomain and C-terminal domain. Mol Pharmacol 2002; 62: 1187–97.
30. Carew MA, Wu M-L, Law GJ et al. Extracellular ATP activates calcium entry and mobilization via P2U-purinoceptors in rat lactotrophs. Cell Calcium 1994; 16: 227–35.
31. Koshimizu T, Tomic M, Koshimizu M, Stojilkovic SS. Identification of amino acid residues contributing to desensitization of the P2X2 receptor channel. J Biol Chem 1998; 273: 12853–7.
32. Brake AJ, Wagenbach MJ, Julius D. New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 1994; 371: 519–23.
33. Unsworth CDJRJ. ATP compartmentation in neuroendocrine secretory vesicles. Ann NY Acad Sci 1990; 603: 353–63.
34. Schwiebert EM. ABC transporter-facilitated ATP conductive transport. Am. J Physiol 1999; 276: C1–8.
35. Joseph SM, Buchjakjian MR, Dubyk GR. Colocalization of ATP release sites and ecto-ATPase activity at the extracellular surface of human astrocytes. J Biol Chem 2003; 278: 23331–42.
36. Van Goor F, Zivadinovic D, Matinez-Fuentes AJ, Stojilkovic SS. Dependence of pituitary hormone secretion on the pattern of spontaneous voltage-gated calcium influx: Cell-type specific action potential-secretion coupling. J Biol Chem 2001; 276: 33840–6.
37. Fauquier T, Guerineau NC, McKinney RA et al. Folliculostellate cell network: A route for long-distance communication in the anterior pituitary. Proc Natl Acad Sci USA 2001; 98: 8891–6.